title: Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.
abstract: BACKGROUND
  Discovery of neurotrophic factors--emblematic: the nerve growth factor (NGF)--resulted in better approaching central nervous system (CNS) lesions. Recently, another crucial property has been unveiled: their rather unique pleiotropic effect. Cerebrolysin is a peptide mixture that penetrates the blood-brain barrier in significant amounts and mimics the effects of NGF.
  
  
  METHODS
  Comparative analysis: Cerebrolysin treated (10 ml x 2/day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy). Two lots of patients, admitted in our Physical & Rehabilitation (neural-muscular) Medical-PR(n-m)M-Clinic Division, during 2007-2009: 69 treated with Cerebrolysin (22 F, 47 M; Average: 59.333; Mean of age: 61.0 Years old; Standard deviation 16.583) and 70 controls (41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270) were studied. The total number of assessed items was 13: most contributive in relation with the score of Functional Independence Measure at discharge (d FIM), were: admission (a FIM), number of physical therapy days (PT), number of hospitalization days (H), age (A) and--relatively--days until the first knee functional extension (KE). Concomitantly, the main/key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters, have been assessed regarding the speed in achieving their functional recovery.
  
  
  RESULTS
  Concerning d FIM, there have not been objectified significant differences between the two lots (p=0.2453) but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE (p=0.0007) and days until the first time recovery of the ability to walk between parallel bars (WPB--p=0.0000)--highly significant differences in favor of Cerebrolysin lot resulted.
  
  
  CONCLUSIONS
  Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a comprehensive national, 5 year retrospective, multi-centre--based on unitary data acquisition frame and mathematical apparatus--study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).
authors.affiliation: Bagdasar-Arseni Teaching Emergency Hospital, Bucharest, Romania.
authors.forename: G
authors.initials: G
authors.lastname: Onose
authors.forename: D F
authors.initials: DF
authors.lastname: Mureşanu
authors.forename: A V
authors.initials: AV
authors.lastname: Ciurea
authors.forename: C
authors.initials: C
authors.lastname: Daia Chendreanu
authors.forename: A S
authors.initials: AS
authors.lastname: Mihaescu
authors.forename: D C
authors.initials: DC
authors.lastname: Mardare
authors.forename: I
authors.initials: I
authors.lastname: Andone
authors.forename: A
authors.initials: A
authors.lastname: Spânu
authors.forename: C
authors.initials: C
authors.lastname: Popescu
authors.forename: A
authors.initials: A
authors.lastname: Dumitrescu
authors.forename: M
authors.initials: M
authors.lastname: Popescu
authors.forename: V
authors.initials: V
authors.lastname: Grigorean
authors.forename: B
authors.initials: B
authors.lastname: Ungur
authors.forename: F
authors.initials: F
authors.lastname: Marinescu
authors.forename: I
authors.initials: I
authors.lastname: Colibbeanu
authors.forename: L
authors.initials: L
authors.lastname: Onose
authors.forename: M
authors.initials: M
authors.lastname: Haras
authors.forename: A
authors.initials: A
authors.lastname: Sandu
authors.forename: T
authors.initials: T
authors.lastname: Spircu
mesh_terms: D000596:Amino Acids / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001930:Brain Injuries / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018697:Nootropic Agents / Q000627:therapeutic use*; D013552:Swine; D013569:Synapses / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D000596:Amino Acids; D018697:Nootropic Agents; C006952:cerebrolysin